
The reversal of Roe v. Wade in Dobbs v. Jackson Women’s Health Organization (2022) has reshaped the legal and moral landscape of reproductive health care in the United States. In this new era of state-level variation and ongoing conscience-driven conflict, the ACGME’s current abortion training standards expose significant fault lines between medical education, law, and ethics. What was once considered a settled requirement of comprehensive reproductive training has become, in many regions, a point of legal contradiction and moral tension. From a bioethical standpoint, the current standards fail to strike an equitable balance among the principles of autonomy, beneficence, nonmaleficence, and justice. By privileging one conception of beneficence, procedural access, over others, the ACGME inadvertently undermines autonomy and justice for institutions and individuals who hold sincere moral objections. Moreover, through the lens of virtue ethics, the standards neglect the formative purpose of medical education: to cultivate physicians of integrity and moral prudence who can navi-gate pluralistic ethical landscapes. This paper proposes a set of four-tiered reforms that reconcile medical competency with conscience and legality: • At the federal level, the separation of GME funding from abortion training ensures compliance with federal appropria-tions law and public accountability. • At the state level, a model of state-consistent compliance respects federalism while maintaining educational equivalence through alternative training pathways. • At the institutional level, conscience-based exemptions safeguard the participation of faith-based hospitals in medical education without diluting academic rigor. • At the individual level, an opt-in framework for abortion training affirms the autonomy and moral agency of each train-ee, fostering authentic professional formation. Collectively, these reforms do not diminish the ACGME’s commitment to high-quality, comprehensive training. Rather, they reorient it towards a more ethically pluralistic and legally coherent model, one that aligns with the values of a diverse society and the principles of professional freedom. Keywords ACGME; abortion training; graduate medical education; conscientious objection; institutional conscience; Dobbs v. Jackson Women’s Health Organization; opt-in training model; medical ethics
Mifepristone was first approved in 2000 in conjunction with misoprostol to induce abortion, and both its initial approval and subsequent regulation have been controversial. In 2021, the Food and Drug Administration (FDA) undertook a full review of the mifepristone Risk Evaluation and Mitigation Strategy (REMS) program, with the aim of assessing the necessity of each of the three Elements to Assure Safe Use (ETASUs) present in the mifepristone REMS, including ETASU C, the “in-person dispensing requirement.” Following this review, the FDA concluded that ETASU C could be safely removed and that mifepristone could be safely dispensed outside of the previously approved settings. This paper seeks to critically analyze the 2021 REMS Review, as well as the studies cited therein to determine whether the evidence presented by the FDA sufficiently substantiated this decision. Factors that render the cited studies non-replicative of real-world, non-study conditions and therefore unable to be generalized to these contexts are highlighted. Differential treatment of stakeholder input and limitations of abortion complication reporting systems are also discussed. The clinical implications of the FDA’s decision to remove ETASU C are noted, followed by several actionable recommendations to the FDA. Keywords: induced abortion; medical abortion; medication abortion; induced termination of pregnancy; mifepristone; Risk Evaluation and Mitigation Strategy; Elements to Assure Safe Use; Food and Drug Administration
Induced abortion, "an intervention intended to terminate a pregnancy so that it does not result in a live birth"1, is a highly contentious procedure, with varying comprehension of actual abortion procedures used. The comprehension of the actual abortion procedure used in the second trimester may affect the various levels of support or lack thereof for abortion after the first trimester. The most common second trimester surgical abortion procedure is Dilation and Evacuation (D&E). Many commonly available descriptions of the D&E lack sufficient detail and may not be sufficient for patients or the public to understand the procedure. Little is known about the public's understanding of D&E abortion procedures. This pilot study investigates how viewing an animated D&E procedure impacts participants' perceived understanding of the procedure, emotional responses, and prolife/prochoice affiliations. Researchers conducted a 14-item pre-and post-intervention survey in the Ohio Valley region (n=50). While participants' pro-life/pro-choice position on abortion did not immediately change after watching the video, participants' perceived understanding of the procedure increased (p<0.05, d=0.45). Furthermore, both prolife and pro-choice cohorts reported a high frequency (70%) of negative emotion when considering abortion after viewing the procedure. Notably, participants who perceived themselves to have a greater knowledge of abortion felt more negative emotion (p<0.05, r=-0.49). In conclusion, the results of this pilot study suggest animated depictions of a D&E abortion procedure increased participants' perceived understanding of abortion, which may demonstrate a lack in current public understanding. In addition, those who are knowledgeable about abortion procedures were found to be more likely to report negative feelings toward the use of D&E procedures and to identify as prolife. Although participants' pro-life/pro-choice position on abortion did not immediately change after watching the video, it is possible that comprehension of the details of a D&E procedure may promote a pro-life identity in the long term. Further long-term research is needed to confirm whether greater abortion knowledge and negative emotional responses promote a long-term pro-life affiliation.
With the deep integration of artificial intelligence and biotechnology, the paradigm of genetic discrimination is undergoing a fundamental transformation. Rather than relying on specific genetic markers, AI systems may infer individuals’ underlying biological risks through proxy data. This emerging form of discrimination, conceptualized in this article as “Algorithmic Proxy Genetic Discrimination” (APGD), is predictive, opaque, and structural. However, China’s existing Personal Information Protection Law and fragmented antidiscrimination framework remain insufficient to address this problem. In addition, APGD raises profound ethical and social challenges. To mitigate these risks, this article proposes a tiered regulatory approach: (1) controlling the misuse of proxy variables at the data input stage; (2) strengthening transparency and auditing in algorithmic decision-making; and (3) establishing an outcome-oriented mechanism for anti-discrimination liability and rights protection.
Past research has shown that steroid hormones and other endocrine-disrupting compounds (EDCs) are present in environmental water, with implications for human and wildlife health. Abortion providers have shifted a large part of their practice to medication-induced abortion, using the anti-progesterone synthetic steroid hormone mifepristone. We wanted to see if mifepristone, an EDC, could be detected in water sources. Water samples were collected from sites upstream and downstream of water treatment facilities and from municipal tap water in each of 3 American cities. The water samples were tested for mifepristone using the PR CALUX (R) assay. There were significant levels of anti-progesterone activity (up to 0.041 mu gram/l) in the water of all but one of the nine sampling classes. Given progesterone's numerous effects, this contaminant could affect the physiology of aquatic animals and human health, including fertility, pregnancy, and fetal development. The findings indicate the significant need for additional investigation into the levels of various hormones and EDCs, including mifepristone, in water sources.